GlassScriptPhysician profile
Steven R Asdell
NPI 1093794034
$2,461.51
in general payments reported to CMS, 2019-2025
25 companies · $222 in 2025
The $222 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $314 · 2021: $340 · 2022: $398 · 2023: $456 · 2024: $368 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $426.97 | 2019-2025 | Dyanavel Xr |
| Corium, LLC | $309.85 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $241.27 | 2019-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Neos Therapeutics, LP | $241.00 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $234.37 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $178.59 | 2019-2022 | |
| Cranial Technologies, INC | $113.60 | 2019-2024 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $89.91 | 2023-2024 | Flumist Quadrivalent |
| Pfizer INC. | $69.19 | 2019-2023 | |
| Sanofi Pasteur INC. | $65.59 | 2020-2024 | |
| Adlon Therapeutics L.P. | $63.42 | 2019-2021 | |
| Seqirus USA INC | $61.40 | 2021-2023 | Flucelvax Quadrivalent |
| Kaleo, INC. | $50.73 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $44.03 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $34.63 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $34.31 | 2025 | Jornay Pm |
| Ptc Therapeutics, INC. | $28.00 | 2023 | |
| Vertical Pharmaceuticals, LLC | $25.78 | 2019-2025 | Relexxii |
| Kyowa Kirin, INC. | $25.59 | 2023 | |
| Sanofi-Aventis U.S. LLC | $24.92 | 2023 | |
| Biogen, INC. | $24.52 | 2023 | Spinraza |
| Sobi, INC | $22.64 | 2019-2021 | |
| Lnhc, INC | $19.44 | 2025 | Zelsuvmi |
| Dermira, INC. | $17.50 | 2020 | |
| Alexion Pharmaceuticals, INC. | $14.26 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Asdell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.